메뉴 건너뛰기




Volumn 7, Issue 2, 2007, Pages 185-197

Molecular mechanism of resistance to antiviral therapy in patients with chronic hepatitis B

Author keywords

Closed circular DNA; Entecavir; Hepatitis B e antigen; Hepatocellular carcinoma (HCC); Lamivudine; Nucleotide ana

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; AMDOXOVIR; ANTIVIRUS AGENT; CLEVUDINE; DNA DIRECTED DNA POLYMERASE ALPHA; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; LDT TYZECKA; LEVO 2' DEOXYADENOSINE; MESSENGER RNA; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR DISOPROXIL; TORCITABINE; UNCLASSIFIED DRUG; VALTORCITABINE; VIRUS DNA;

EID: 33947699267     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652407780059159     Document Type: Review
Times cited : (15)

References (124)
  • 62
    • 0036434586 scopus 로고    scopus 로고
    • Zoulim, F. (2002) Semin. Liver Dis., 22 (Suppl 1), 23-31.
    • (2002) Semin. Liver Dis. , vol.22 , Issue.SUPPL. 1 , pp. 23-31
    • Zoulim, F.1
  • 74
    • 33746210394 scopus 로고    scopus 로고
    • Briefing document for NDA 21-797, entecavir 0.5 and 1 mg tablets and NDA 21-798, entecavir oral solution 0.05 mg/mL
    • Entecavir Review Team. on World Wide Web URL
    • Entecavir Review Team. Briefing document for NDA 21-797, entecavir 0.5 and 1 mg tablets and NDA 21-798, entecavir oral solution 0.05 mg/mL. on World Wide Web URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4094B1_02_FDA-Background-Memo.pdf
  • 115


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.